Research and Markets (http://www.researchandmarkets.com/research/m763b6/chemotherapy) has announced the addition of the "Chemotherapy Induced Pain-Pipeline Insights, 2014" subscription to their offering.
This Chemotherapy Induced Pain-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Chemotherapy Induced Pain.
This report provides information on the therapeutic development based on the Chemotherapy Induced Pain dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Key Topics Covered:
- Chemotherapy Induced Pain Overview
- Chemotherapy Induced Pain Pipeline Therapeutics
- Chemotherapy Induced Pain Therapeutics under Development by Companies
- Chemotherapy Induced Pain Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Chemotherapy Induced Pain Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Chemotherapy Induced Pain Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Chemotherapy Induced Pain Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Chemotherapy Induced Pain - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chemotherapy Induced Pain - Discontinued Products
- Chemotherapy Induced Pain - Dormant Products
- Companies Involved in Therapeutics Development for Chemotherapy Induced Pain
- Appendix
For more information visit http://www.researchandmarkets.com/research/m763b6/chemotherapy